Summary
Type III Gaucher disease is one of the three recognized subtypes of Gaucher disease, an inherited deficiency of lysosomal glucocerebrosidase. Phenotypically there is a wide spectrum of visceral and neurological manifestations. Enzyme replacement is effective in managing the visceral disease; however, the neurological manifestations remain a more challenging obstacle. There is an unfulfilled need to reliably monitor neurological disease and its response to treatment. A severity scoring tool was developed through neurological domain identification, item generation and tool formation. Domain identification was established based on a retrospective single centre study (n=15) and a systematic review of publications. Forty-seven patients with neuronopathic Gaucher disease were then assessed using the tool to establish the clinical and statistical reliability of each domain. Judgement quantification of the tool was established through a process of content validity involving five European experts. Content validity is considered to be most effective when undertaken systematically. Concurrent validity and feasibility of the tool was also highlighted. This process allowed a revised and validated version of the tool to be developed.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Abrahamov A, Elstein D, Gross-Tsur V, et al (1995) Gaucher’s disease variant characterised by progressive calcification of heart valve and unique genotype. The Lancet 346: 1000–1003.
Altarescu G, Hill S, Wiggs E, et al (2001) The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher’s disease. J Pediatr 138(4): 539–547.
Bowling, A (2001) Measuring Disease, 2nd edn. Milton Keynes: Open University Press.
DeVellis RF. (1991) Scale Development: Theory and Applications. Newbry Park, CA: Sage Publications.
Durling E, Dale N, Davies E, Vellodi A (2006) Understanding the cognitive profile of children with neuronopathic Gaucher disease. Poster presentation. European Working Group on Gaucher Disease, Cambridge July 2006.
Erikson A, Dreborg S, Hagberg B (1980) Gaucher disease — Norrbottnian type. General clinical description. Eur J Pediatr 133(2): 107–118.
Erikson A, Astrom M, Mansson JE (1995) Enzyme infusion therapy of the Norrbottnian (Type 3) Gaucher disease. Neuropediatrics 26(4): 203–207.
Erikson A, Forsberg H, Nilsson M, et al (2006) Ten years’ experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease. Acta Paediatr 95(3): 312–317.
Gibson F, Cargill J, Allison J, et al (2006) Establishing content validity of the oral assessment guide in children and young people. Eur J Cancer 42(12): 1–9.
Goldblatt J, Szer JM, Fletcher J, et al (2005) Enzyme replacement therapy for Gaucher disease in Australia. Int Med J 35: 156–161.
Ida H, Rennert OM, Iwasawa K, Kob (1999) Clinical and genetic studies of Japanese homozygotes for the Gaucher disease L444P mutation. Hum Genet 105(1–2): 120–126.
Lynn MR (1986) Determination and quantification of content validity. Res Nurs Health 35(6): 382–385.
Oppenheim A (2003) Questionnaire, Design, Interviewing and Attitude Measurement. New York: Continuum.
Park JK, Orvisky E, Tayebi N, et al (2003) Myoclonic epilepsy in Gaucher disease: genotype–phenotype insights from a rare patients subgroup. Pediatr Res 53(3): 387–395.
Pasmanik-Chor M, Laadan S, Elroy-Stein O, et al (1996) The glucocerebrosidase D409H mutation in Gaucher disease. Biochem Mol Med 59(2): 125–133.
Richmond JP, Wright ME (2005) Development of a constipation risk assessment scale. Clin Effect Nurs 9: 37–48.
Ruperto N, Giannini EH (1996) Redundancy of conventional articular response variables used in juvenile chronic arthritis clinical trials. Ann Rheum Dis 55(1): 73–75.
Rusca CL (1921) Sul morbo del Gaucher. Hematologica 2: 441.
Rust J, Golombok S (1995) Modern Psychometrics. The Science of Psychological Assessment. London: Routledge.
Seong TJ (2002) Validity and Reliability. Seoul: Hakjsa.
Schmitz-Hubsch T, du Montcel ST, Baliko L, et al (2006) Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 13: 1717–1720.
Steinfield R, Heim P, von Gregory H, et al (2002) Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations. Am J Med Genet 112: 347–354.
Tylki-Szymanska A, Keddache MS, Grabowski GA (2006) Characterization of neuronopathic Gaucher disease among ethnic Poles. Genet Med 8(1): 8–15.
van den Hout HM, Hop W, van Diggelen OP (2003) The natural course of infantile Pompe’s disease: 20 orignial cases compared with 133 cases from the literature. Pediatrics 112: 332–340.
Vellodi A, Bembi B, de Villemeur TB, et al (2001) Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis 24: 319–327.
Whybra C, Kampmann C, Krummeneauer F et al (2004) The Mainz Severity Index: a new instrument for quantifying the Anderson-Fabry disease phenotype and response of patients to enzyme replacement therapy. Clin Genet 65: 299–307.
Woolery M, Carroll E, Fenn E, et al (2006) A constipation assessment scale for use in pediatric oncology. Pediatr Oncol Nurs 23(2): 65–74.
Zimran A, Sorge J, Gross E, Kubitz M, West C, Beutler E (1989) Prediction of severity of Gaucher’s disease by identification of mutations at DNA level. Lancet. 2: 349–352.
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicating editor: Georg Hoffmann
Competing interests: None declared
References to electronic databases: PubMed
Rights and permissions
About this article
Cite this article
Davies, E.H., Surtees, R., DeVile, C. et al. A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease. J Inherit Metab Dis 30, 768–782 (2007). https://doi.org/10.1007/s10545-007-0595-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10545-007-0595-x